![Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrclinonc.2013.208/MediaObjects/41571_2014_Article_BFnrclinonc2013208_Fig1_HTML.jpg)
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology
![Frontiers | The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? Frontiers | The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?](https://www.frontiersin.org/files/Articles/574271/fimmu-11-574271-HTML-r2/image_m/fimmu-11-574271-g001.jpg)
Frontiers | The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
![The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications | Cellular & Molecular Immunology The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications | Cellular & Molecular Immunology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41423-020-0488-6/MediaObjects/41423_2020_488_Fig1_HTML.png)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications | Cellular & Molecular Immunology
![CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade: Molecular Therapy - Nucleic Acids CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/44b8c0ac-0b8b-4621-adbe-85f6e4b1ea88/fx1_lrg.jpg)
CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade: Molecular Therapy - Nucleic Acids
![Biology | Free Full-Text | Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors Biology | Free Full-Text | Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors](https://pub.mdpi-res.com/biology/biology-12-00218/article_deploy/html/images/biology-12-00218-g001.png?1675217709)